RxDoctor Payments Data

Petra Grinnell

Family · San Antonio, TXNPI 1386959120

Payments from drug & device makers

$5,032in general payments, 2019–2025

Across 253 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$835
  • Amgen$527
  • Corcept Therapeutics$337
  • Novo Nordisk$296
  • Boehringer Ingelheim$288
  • Radius Health, Inc.$235
  • plus $3K from 29 others

What the payments were for

  • Food & beverage$5,032100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,032 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$66,249
GenotropinSomatropin25$47,959
ProliaDenosumab22$38,136
TymlosAbaloparatide11$27,392
MounjaroTirzepatide20$19,877
SynthroidLevothyroxine Sodium232$14,797
Levothyroxine Sodium1,115$13,215
Humalog Kwikpen U-100Insulin Lispro39$8,923
Lantus SolostarInsulin Glargine,hum.Rec.Anlog53$5,598
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$5,130
Insulin Lispro Kwikpen U-100Insulin Lispro14$3,374
Nano 2nd Gen Pen NeedlePen Needle, Diabetic19$2,803
Hydrocortisone31$1,924
Alendronate Sodium95$909
Ibandronate Sodium27$843

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$296$66,24957 claims
AmgenProlia$527$38,13622 claims
Radius Health, Inc.Tymlos$235$27,39211 claims
Lilly USA, LLCMounjaro$835$19,87720 claims
AbbVieSynthroid$155$14,797232 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$30$13,2151,115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.

Other family in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →